These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30967527)

  • 1. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
    Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
    Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
    Che F; Ye X; Wang Y; Ma S; Wang X
    Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
    Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
    Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
    Tang JX; Chen Q; Li Q; He YH; Xiao D
    Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α.
    Wang M; Zhao HY; Zhang JL; Wan DM; Li YM; Jiang ZX
    Exp Cell Res; 2020 Nov; 396(1):112280. PubMed ID: 32961145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
    Nian F; Zhu J; Chang H
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212.
    Wang R; Zhao L; Ji L; Bai L; Wen Q
    Biomed Pharmacother; 2019 Oct; 118():109298. PubMed ID: 31404776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
    Wang L; Cao J; Tao J; Liang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.
    Bao L; Wang Y; Lu M; Shi L; Chu B; Gao S
    Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130299. PubMed ID: 36565997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214.
    Huang X; Gao Y; Qin J; Lu S
    Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G559-G565. PubMed ID: 29097358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rs1894720 polymorphism in MIAT increased susceptibility to age-related hearing loss by modulating the activation of miR-29b/SIRT1/PGC-1α signaling.
    Hao S; Wang L; Zhao K; Zhu X; Ye F
    J Cell Biochem; 2019 Apr; 120(4):4975-4986. PubMed ID: 30556210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.